Skip to main content

Vaginal tablets of dequalinium chloride 10 mg versus clotrimazole 100 mg for vaginal candidiasis: a double-blind, randomized study



To compare the clinical response, microscopic examination and fungal culture between dequalinium chloride (DQC) and clotrimazole (CT) for treating vaginal candidiasis (VC).


The double-blind, randomized study was conducted from September 2014 to September 2016 at Siriraj Hospital, Thailand. Eligible participants were Thai women diagnosed with VC by microscopic examination. The exclusion criteria included immunocompromised conditions, consumption of antifungal drugs, and having recurrent VC. Each participant was randomized with a 1:1 allocation to receive six vaginal tablets of 100 mg CT or 10 mg DQC. Two visits included 10 ± 2 days (C1) and 38 ± 4 days (C2). Outcome measures were improvement of VC symptoms, microscopic examination, culture, satisfaction and tolerability.


Of 155 eligible participants, 150 were randomized and allocated into CT (N = 76) and DQC (N = 74). The average age was 31.1 ± 7.2 years. Comparable improvement of clinical response was demonstrated (OR at C1 0.79, 95% CI 0.56–1.10, p = 0.197; and OR at C2 0.99, 95% CI 0.69–1.43, p = 0.985). Of CT and DQC groups, the microscopic examination was positive at 11/75 (14.9%) vs 18/72 (25.3%) at C1 and 18/74 (24.3%) vs 28/66 (42.4%) at C2. And the culture was positive at 25/75 (33.8%) vs 46/72 (65.7%) at C1 and at 26/74 (36.6%) vs 46/66 (69.7%) at C2. Most participants had high satisfaction and tolerability and none reported any side effects.


DQC and CT show comparable clinical response but CT results in greater improvement of microscopic examination and fungal culture.

Clinical trial registration

The Clinical Trial Registry number was NCT02242695. (September 17, 2014)

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Availability of data and material


Code availability



  1. 1.

    Chayachinda C, Thamkhantho M, Chalermchockcharoenkit A, Nuengton C, Thipmontree W (2018) Characteristics of Clients at the Siriraj Female STD Clinic during 2011–2015. Siriraj Med Bull 11:182–189

    Google Scholar 

  2. 2.

    Sobel JD (1997) Vaginitis. N Engl J Med 337:1896–1903.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Unit of Medical Statistics, Department of Obstetrics and Gynaecology, Faculty of Medicine Siriraj Hospital (2018) Annual report of medical statistics. 2010–2018. P.A. Living Co., Ltd., Bangkok

    Google Scholar 

  4. 4.

    Jacob L, John M, Kalder M, Kostev K (2018) Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients. Curr Med Mycol 4:6–11.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS (2002) Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 99:419–425.

    Article  PubMed  Google Scholar 

  6. 6.

    Sobel JD (2007) Vulvovaginal candidosis. Lancet 369:1961–1971.

    Article  PubMed  Google Scholar 

  7. 7.

    Workowski K, Bolan G (2015) Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64:75–78

    Google Scholar 

  8. 8.

    Faculty of Sexual and Reproductive Healthcare (2012) Management of vaginal discharge in non-genitourinary Medicine settings 2012. Accessed 3 Mar 2020

  9. 9.

    Wachtler B, Wilson D, Hube B (2011) Candida albicans adhesion to and invasion and damage of vaginal epithelial cells: stage-specific inhibition by clotrimazole and bifonazole. Antimicrob Agents Chemother 55:4436–4439.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    O-prasertsawat P, Bourlert A (1995) Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. Sex Transm Dis 22:228–230.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Sekhavat L, Tabatabaii A, Tezerjani FZ (2011) Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. J Infect Public Health 4:195–199.

    Article  PubMed  Google Scholar 

  12. 12.

    Cohen L (1985) Is more than one application of an antifungal necessary in the treatment of acute vaginal candidiasis? Am J Obstet Gynecol 152:961–964.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Lebherz T, Guess E, Wolfson N (1985) Efficacy of single- versus multiple-dose clotrimazole therapy in the management of vulvovaginal candidiasis. Am J Obstet Gynecol 152:965–968.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B et al (1995) Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 172:1263–1268.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Ahangari F, Farshbaf-Khalili A, Javadzadeh Y, Adibpour M, Sadeghzadeh Oskouei B (2019) Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: a randomized, controlled clinical trial. J Obstet Gynaecol Res 45:897–907.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A (2007) Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev.

    Article  PubMed  Google Scholar 

  17. 17.

    Pristov KE, Ghannoum MA (2019) Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect 25:792–798.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Sobel JD, Sobel R (2018) Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother 19:971–977.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Mendling W, Weissenbacher ER, Gerber S, Prasauskas V, Grob P (2016) Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet 293:469–484.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G (2002) Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung 52:699–705.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Turner RJ, Taylor DE, Weiner JH (1997) Expression of Escherichia coli TehA gives resistance to antiseptics and disinfectants similar to that conferred by multidrug resistance efflux pumps. Antimicrob Agents Chemother 41:440–444

    CAS  Article  Google Scholar 

  22. 22.

    Petersen EE, Weissenbacher ER, Hengst P, Spitzbart H, Weise W, Wolff F et al (2002) Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimittelforschung 52:706–715.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Kolbe H (1972) Treatment of infectious vaginal fluor with Dequavagyn. Ther Ggw 111:415–420

    CAS  PubMed  Google Scholar 

  24. 24.

    Atlante G (1959) A new chemotherapeutic agent in the treatment of vaginitis due to Trichomonas and Candida. Minerva Ginecol 11:588–591

    CAS  PubMed  Google Scholar 

  25. 25.

    Yano J, Sobel JD, Nyirjesy P, Sobel R, Williams VL, Yu Q et al (2019) Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health 19:48.

    Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Weissenbacher ER, Donders G, Unzeitig V, Martinez de Tejada B, Gerber S, Halaska M et al (2012) A comparison of dequalinium chloride vaginal tablets (Fluomizin(R)) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest 73:8–15.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information




MT: project development, data collection, and manuscript writing. CC: data analysis and manuscript writing.

Corresponding author

Correspondence to Chenchit Chayachinda.

Ethics declarations

Conflict of interest

The study was financially supported by Medinova AG, Switzerland. M Thamkhantho had received honoraria as occasionally being the product speaker.

Consent to participate


Consent for publication


Ethics approval

The Siriraj Institutional Review Board (COA. no. Si226/2013).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Thamkhantho, M., Chayachinda, C. Vaginal tablets of dequalinium chloride 10 mg versus clotrimazole 100 mg for vaginal candidiasis: a double-blind, randomized study. Arch Gynecol Obstet 303, 151–160 (2021).

Download citation


  • Clotrimazole
  • Dequalinium chloride
  • Randomized
  • Treatment
  • Vaginal candidiasis